首页|双歧杆菌四联活菌对宫颈癌化疗患者肠道菌群、免疫功能及化疗神经毒性的影响

双歧杆菌四联活菌对宫颈癌化疗患者肠道菌群、免疫功能及化疗神经毒性的影响

扫码查看
目的:探讨双歧杆菌四联活菌片对宫颈癌化疗患者肠道菌群、免疫功能及化疗神经毒性的影响。方法:选取2021年5月至2023年5月该院收治的宫颈癌患者92例,开展前瞻性研究。采用电脑随机数字表法将患者分为对照组、研究组,各46例。对照组患者行TP方案(紫杉醇+顺铂)化疗,研究组患者行双歧杆菌四联活菌片辅助TP化疗方案治疗,21 d为1个周期,均治疗4个周期。比较两组患者的近期疗效,治疗前后肠道菌群、免疫功能指标[T淋巴细胞亚群(CD3+、CD4+和CD4+/CD8+)、免疫球蛋白A(IgA)和免疫球蛋白G(IgG)]水平、血清疗效相关标志物[细胞角蛋白19片段抗原21-1(CYFRA21-1)、成纤维细胞生长因子受体4(FGFR4)和Spondin-2]水平、生活质量及治疗期间化疗不良反应发生情况。结果:研究组患者的总缓解率、总有效率分别为69。57%(32/46)、82。61%(38/46),与对照组的 60。87%(28/46)、71。74%(33/46)比较,差异均无统计学意义(P>0。05)。研究组患者治疗2、4个周期后的双歧杆菌、乳杆菌和肠球菌菌落数高于对照组,大肠杆菌菌落数低于对照组;研究组患者治疗2、4个周期后的外周血CD3+、CD4+和CD4+/CD8+水平,血清IgA、IgG水平高于对照组;研究组、对照组患者治疗2、4个周期后的血清CYFRA21-1、FGFR4和Spondin-2水平低于治疗前;研究组患者治疗2、4个周期后的QOL、KPS评分高于对照组,上述差异均有统计学意义(P<0。05)。研究组患者治疗期间胃肠道反应、肾功能损伤、白细胞减少和神经毒性的发生率低于对照组,差异均有统计学意义(P<0。05)。结论:双歧杆菌四联活菌片能减轻化疗对宫颈癌患者肠道菌群、免疫功能的影响,有助于降低化疗神经毒性等不良反应发生率,改善患者生活质量。
Effects of Bifidobacterium Quadruple Viable Tablets on Intestinal Flora,Immune Function and Chemotherapeutic Neurotoxicity in Patients Undergoing Chemotherapy for Cervical Cancer
OBJECTIVE:To probe into the effects of Bifidobacterium quadruple viable tablets on intestinal flora,immune function and chemotherapeutic neurotoxicity in patients undergoing chemotherapy for cervical cancer.METHODS:A total of 92 patients with cervical cancer admitted into the hospital from May 2021 to May 2023 were selected for prospective study.All patients were divided into the control group and research group via random number table method,with 46 cases in each group.The control group was given TP regimen(paclitaxel+cisplatin)for chemotherapy,and the research group received Bifidobacterium quadruple viable tablets combined with TP regimen for chemotherapy,with 21 d as 1 cycle,both groups were treated for 4 cycles.The short-term efficacy of both groups,the intestinal flora,immune function indicators[T-lymphocyte subpopulations(CD3+,CD4+and CD4+/CD8+),immunoglobulin A(IgA)and immunoglobulin G(IgG)],serum efficacy-related markers[cytokeratin 19 fragment antigen 21-1(CYFRA21-1),fibroblast growth factor receptor 4(FGFR4)and Spondin-2]levels before and after treatment,quality of life and incidences of adverse drug reactions during chemotherapy were compared.RESULTS:The overall remission rate and total effective rate of the research group were respectively 69.57%(32/46)and 82.61%(38/46),the differences were not statistically significant(P>0.05)when compared with 60.87%(28/46)and 71.74%(33/46)of the control group.The numbers of Bifidobacterium,Lactobacillus and Enterococcus colonies were higher,the number of Escherichia coli colonies was lower in the research group than those in the control group after 2 and 4 cycles of treatment;the CD3+,CD4+and CD4+/CD8+levels in peripheral blood,and the serum IgA and IgG levels in the research group were higher than those in the control group after 2 and 4 cycles of treatment;the serum CYFRA21-1,FGFR4 and Spondin-2 levels in the research group and the control group after 2 and 4 cycles of treatment were lower than those before treatment;the QOL and KPS scores of the research group were higher than those of the control group after 2 and 4 cycles of treatment,the differences were statistically significant(P<0.05).The incidences of gastrointestinal reactions,renal function impairment,leukopenia and neurotoxicity during treatment in the research group were lower than those of the control group,with statistically significant differences(P<0.05).CONCLUSIONS:Bifidobacterium quadruple viable tablets can relieve the effects of chemotherapy on intestinal flora and immune function of patients with cervical cancer,which helps to reduce the incidence of adverse drug reactions such as chemotherapy neurotoxicity and improve patients'quality of life.

Cervical cancerBifidobacterium quadruple viable tabletsChemotherapyIntestinal floraImmune functionChemotherapeutic neurotoxicity

马喆恒、曹梦颖、王伟、修丽娟、王群

展开 >

徐州市中心医院药剂科,江苏徐州 221000

徐州市中心医院肿瘤内科,江苏徐州 221000

宫颈癌 双歧杆菌四联活菌片 化疗 肠道菌群 免疫功能 化疗神经毒性

江苏省优势学科建设工程项目

YSHL2105-072

2024

中国医院用药评价与分析
中国医药生物技术协会,中国药房杂志社

中国医院用药评价与分析

CSTPCD
影响因子:1.142
ISSN:1672-2124
年,卷(期):2024.24(8)